$ICCC
IMMUCELL CORP /DE/ Stock $iccc

$iccc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024028718 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$7.258M	$5.096M	$17.47M
YoY Change	110.58%	30.3%	-5.9%
Cost Of Revenue	$4.962M	$3.838M	$13.60M
YoY Change	57.74%	31.48%	24.58%
Gross Profit	$2.295M	$1.258M	$3.869M
YoY Change	663.15%	26.81%	-49.42%
Gross Profit Margin	31.63%	24.69%	22.14%
Selling, General & Admin	$1.333M	$1.195M	$5.222M
YoY Change	-7.85%	-24.18%	-4.25%
% of Gross Profit	58.07%	94.99%	134.97%
Research & Development	$1.263M	$1.066M	$4.395M
YoY Change	13.71%	1.52%	-2.2%
% of Gross Profit	55.0%	84.74%	113.6%
Depreciation & Amortization	$662.5K	$677.0K	$2.717M
YoY Change	1.59%	12.04%	10.07%
% of Gross Profit	28.86%	53.82%	70.22%
Operating Expenses	$2.595M	$2.261M	$9.617M
YoY Change	1.51%	-13.9%	-3.33%
Operating Profit	-$300.1K	-$1.003M	-$5.748M
YoY Change	-86.7%	-38.62%	150.02%
Interest Expense	$146.0K	-$135.0K	-$379.0K
YoY Change	62.25%	366.57%	-208.75%
% of Operating Profit
Other Income/Expense, Net	-$136.5K	-$135.0K	-$22.00K
YoY Change	137.39%	321.88%	-88.24%
Pretax Income	-$436.5K	-$1.138M	-$5.770M
YoY Change	-81.13%	-31.69%	132.1%
Income Tax	$1.340K	$2.000K	$5.000K
% Of Pretax Income
Net Earnings	-$437.9K	-$1.140M	-$5.775M
YoY Change	-81.09%	-31.65%	131.56%
Net Earnings / Revenue	-6.03%	-22.37%	-33.05%
Basic Earnings Per Share	-$0.06		-$0.75
Diluted Earnings Per Share	-$0.06	-$0.15	-$0.75
COMMON SHARES
Basic Shares Outstanding	7.751M shares	7.751M shares	7.748M shares
Diluted Shares Outstanding	7.751M shares		7.748M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$960.4K	$978.7K	$978.7K
YoY Change	-68.98%	-83.1%	-83.1%
Cash & Equivalents	$960.3K	$978.7K	$978.7K
Short-Term Investments
Other Short-Term Assets	$562.6K	$454.2K	$454.2K
YoY Change	-17.49%	24.81%	24.81%
Inventory	$7.150M	$7.812M	$7.812M
Prepaid Expenses	$426.1K	$454.2K
Receivables	$2.623M	$2.185M	$2.185M
Other Receivables	$52.63K	$39.74K	$39.74K
Total Short-Term Assets	$11.35M	$11.47M	$11.47M
YoY Change	-7.35%	-18.04%	-18.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.98M	$32.15M	$32.15M
YoY Change	-5.2%	13.03%	4.93%
Goodwill	$95.56K	$95.56K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$46.25K	$57.66K	$57.66K
YoY Change	-47.31%	-24.75%	-24.76%
Total Long-Term Assets	$31.70M	$32.34M	$32.34M
YoY Change	2.68%	4.77%	4.77%
TOTAL ASSETS
Total Short-Term Assets	$11.35M	$11.47M	$11.47M
Total Long-Term Assets	$31.70M	$32.34M	$32.34M
Total Assets	$43.05M	$43.81M	$43.81M
YoY Change	-0.17%	-2.35%	-2.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$737.3K	$887.7K	$887.7K
YoY Change	-7.24%	12.37%	12.37%
Accrued Expenses	$1.670M	$1.685M	$1.685M
YoY Change	98.63%	54.05%	54.05%
Deferred Revenue
YoY Change
Short-Term Debt	$10.10M	$0.00	$0.00
YoY Change	910.37%
Long-Term Debt Due	$1.444M	$1.429M	$1.429M
YoY Change	35.67%	37.46%	37.46%
Total Short-Term Liabilities	$4.184M	$4.197M	$4.197M
YoY Change	9.02%	36.63%	36.63%
LONG-TERM LIABILITIES
Long-Term Debt	$10.17M	$10.54M	$10.54M
YoY Change	14.04%	14.68%	14.68%
Other Long-Term Liabilities	$4.062M	$4.077M	$4.077M
YoY Change	84.01%	83.87%	83.87%
Total Long-Term Liabilities	$14.23M	$14.62M	$14.62M
YoY Change	27.93%	28.13%	28.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.184M	$4.197M	$4.197M
Total Long-Term Liabilities	$14.23M	$14.62M	$14.62M
Total Liabilities	$18.41M	$18.82M	$18.82M
YoY Change	23.08%	29.93%	29.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.44M	-$12.01M
YoY Change	45.6%	92.65%
Common Stock	$37.22M	$37.14M
YoY Change	4663.11%	4652.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.64M	$24.99M	$24.99M
YoY Change
Total Liabilities & Shareholders Equity	$43.05M	$43.81M	$43.81M
YoY Change	-0.17%	-2.35%	-2.35%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$437.9K	-$1.140M	-$5.775M
YoY Change	-81.09%	-31.65%	131.56%
Depreciation, Depletion And Amortization	$662.5K	$677.0K	$2.717M
YoY Change	1.59%	12.04%	10.07%
Cash From Operating Activities	$418.5K	-$724.2K	-$4.674M
YoY Change	-115.15%	-44.2%	202.76%
INVESTING ACTIVITIES
Capital Expenditures	$70.36K	$82.51K	$1.893M
YoY Change	-89.69%	-94.46%	-52.39%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$115.1K	$2.470K
YoY Change	-100.0%		-77.55%
Cash From Investing Activities	-$70.36K	$29.96K	-$1.890M
YoY Change	-89.69%	-102.01%	-52.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$366.5K	-318.5K	1.751M
YoY Change	-148.96%	28.34%	57.19%
NET CHANGE
Cash From Operating Activities	$418.5K	-724.2K	-4.674M
Cash From Investing Activities	-$70.36K	29.96K	-1.890M
Cash From Financing Activities	-$366.5K	-318.5K	1.751M
Net Change In Cash	-$18.39K	-1.013M	-4.813M
YoY Change	-99.32%	-66.64%	9.53%
FREE CASH FLOW
Cash From Operating Activities	$418.5K	-$724.2K	-$4.674M
Capital Expenditures	$70.36K	$82.51K	$1.893M
Free Cash Flow	$348.1K	-$806.7K	-$6.567M
YoY Change	-110.11%	-71.06%	18.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity File Number EntityFileNumber	001-12934
CY2023	dei	Entity Registrant Name EntityRegistrantName	ImmuCell Corporation
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	01-0382980
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	56 Evergreen Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Portland
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	ME
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	04103
CY2023	dei	City Area Code CityAreaCode	(207)
CY2023	dei	Local Phone Number LocalPhoneNumber	878-2770
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.10 par value per share
CY2023	dei	Trading Symbol TradingSymbol	ICCC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	31165000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7750864	shares
CY2023	dei	Auditor Firm AuditorFirmId	344
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Name AuditorName	WIPFLI LLP
CY2023	dei	Auditor Location AuditorLocation	Radnor, Pennsylvania
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	978741	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5791562	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2185383	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1758600	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7811841	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6038539	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	493885	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	406055	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11469850	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13994756	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27575683	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28441726	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4571149	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2194670	usd
CY2023Q4	us-gaap	Goodwill Goodwill	95557	usd
CY2022Q4	us-gaap	Goodwill Goodwill	95557	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38208	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57312	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	57655	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	76628	usd
CY2023Q4	us-gaap	Assets Assets	43808102	usd
CY2022Q4	us-gaap	Assets Assets	44860649	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1428807	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1039447	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	644276	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	31764	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2124337	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2000862	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4197420	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3072073	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	10540496	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9191109	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4077109	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2217418	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	14617605	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7747686	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7745122	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	32576940	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2493805	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30670	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	266244	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	30380049	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11408527	usd
CY2023Q4	us-gaap	Liabilities Liabilities	18815025	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14480600	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7814165	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7814165	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7750864	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7746864	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	781417	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	781417	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	36357239	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35978364	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12007097	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6232499	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	67301	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	67301	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	138482	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	147233	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	24993077	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	30380049	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43808102	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44860649	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17471669	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18567962	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13602385	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10919183	usd
CY2023	us-gaap	Gross Profit GrossProfit	3869284	usd
CY2022	us-gaap	Gross Profit GrossProfit	7648779	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4394852	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4493872	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3088215	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3190033	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2134295	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2263817	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9617362	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9947722	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5748078	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2298943	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21893	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-187190	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5769971	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2486133	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4627	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7672	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5774598	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2493805	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7747686	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7745122	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5774598	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18760	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	368866	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	24993077	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5774598	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2493805	usd
CY2023	us-gaap	Depreciation Depreciation	2697897	usd
CY2022	us-gaap	Depreciation Depreciation	2468479	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19104	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19104	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	13072	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7658	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	9547	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	368866	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	266244	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8099	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	7334	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	95724	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	28476	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	426783	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-935629	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1773302	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2948565	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	87830	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	110858	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-18973	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	50513	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	156995	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	341614	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4674236	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1543871	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1892513	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3975274	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2474	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1890039	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3964274	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	3000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2000000	usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2000000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	1185774	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	897125	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2000000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	35425	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	19306	usd
CY2023	iccc	Payments Of Debt Discounts PaymentsOfDebtDiscounts	46107	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18760	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30670	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1751454	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1114239	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4812821	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4393906	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5791562	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10185468	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	978741	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5791562	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	6466	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	4923	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	444954	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	338516	usd
CY2023	iccc	Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses	50086	usd
CY2022	iccc	Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses	-44998	usd
CY2023	iccc	Change In Payments Of Debt Discounts Included In Accounts Payable And Accrued Expenses ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses	16566	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2472203	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1184727	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>1. BUSINESS OPERATIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ImmuCell Corporation (the “Company”, “we”, “us”, “our”) was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. As disclosed in Note 17, “Segment Information”, one of our business segments is dedicated to Scours and the other is focused on Mastitis. We manufacture and market the <b>First Defense<sup>®</sup></b> product line, providing <b>Immediate Immunity™</b> to prevent scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting <i>E. coli</i>, coronavirus and rotavirus pathogens. We are also in the late stages of developing <b>Re-Tain<sup>®</sup></b>, a treatment for lactating dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key individuals and third-party providers of critical goods and services, competition from other larger companies, the successful sale of existing products and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of the conditions, trends and concerns related to or arising from inflation, rising interest rates and potential recessionary conditions in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We are experiencing price increases in key components, supportive services, transportation and other supplies that are causing our costs of goods sold to increase. We have experienced some contamination events in our production process. We implemented a production slowdown to remediate this problem, which led to the recognition of lower sales and gross margin during the first ten months of 2023.</span></p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Salvage Value Percentage PropertyPlantAndEquipmentSalvageValuePercentage	0.87	pure
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	978741	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	10431817	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5791562	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	8897197	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(j) Concentration of Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During the Years Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company B</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Trade accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As of<br/> December 31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As of<br/> December 31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company B</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company C</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal"></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">This amount is less than 10%.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p>
CY2023	iccc	Accounts Receivable Percentage AccountsReceivablePercentage	0.10	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	368866	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	266244	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	618500	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	605000	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5774598	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2493805	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7747686	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7745122	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7747686	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7745122	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(p) Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation of inventory, long-lived assets, deferred tax assets and costs of goods sold.</span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	978741	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5791562	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2185383	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1758600	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1594028	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2419982	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5815194	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3468702	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	402619	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	149855	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7811841	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6038539	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	527133	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	589204	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	454152	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	363877	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	39733	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	42178	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	493885	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	406055	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	13175	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	63261	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	942999	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	966553	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	97800	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	874558	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	726736	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46059631	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44317346	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18483948	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15875620	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27575683	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28441726	usd
CY2023	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	100142	usd
CY2022	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	127127	usd
CY2023	us-gaap	Depreciation Depreciation	2697897	usd
CY2022	us-gaap	Depreciation Depreciation	2468479	usd
CY2023Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	191040	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19104	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19104	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38208	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57312	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	152832	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38208	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	133728	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57312	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	95550	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	192754	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	143872	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3051	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4890	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2124337	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2000862	usd
CY2022Q1	us-gaap	Participating Mortgage Loans Unamortized Debt Discount Amount ParticipatingMortgageLoansUnamortizedDebtDiscountAmount	2000000	usd
CY2022Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0358	pure
CY2023Q4	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0353	pure
CY2020Q1	us-gaap	Line Of Credit LineOfCredit	1000000	usd
CY2023Q3	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.05	pure
CY2023Q4	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	168268	usd
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred	98098	usd
CY2022	us-gaap	Interest Costs Incurred InterestCostsIncurred	19306	usd
CY2023	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	1000000	usd
CY2022	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	1000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	3000000	usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	1185774	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2000000	usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	897125	usd
CY2023Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	1000000	usd
CY2023Q4	iccc	Debt Issuance Costs2023 DebtIssuanceCosts2023	19076	usd
CY2023Q4	iccc	Debt Issuance Costs2024 DebtIssuanceCosts2024	18976	usd
CY2023Q4	iccc	Debt Issuance Costs2025 DebtIssuanceCosts2025	13579	usd
CY2023Q4	iccc	Debt Issuance Costs2026 DebtIssuanceCosts2026	5420	usd
CY2023Q4	iccc	Debt Issuance Costs2027 DebtIssuanceCosts2027	3513	usd
CY2023Q4	iccc	Debt Issuance Costshereafter DebtIssuanceCostshereafter	11347	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	71911	usd
CY2023Q4	iccc	Debt Discount Cost DebtDiscountCost	20891	usd
CY2023Q4	iccc	Debt Discount Cost2024 DebtDiscountCost2024	20891	usd
CY2023Q4	iccc	Debt Discount Cost2025 DebtDiscountCost2025	11344	usd
CY2023Q4	iccc	Debt Discount Cost Total DebtDiscountCostTotal	53126	usd
CY2023Q4	iccc	Long Term Debt2023 LongTermDebt2023	1428807	usd
CY2023Q4	iccc	Long Term Debt2024 LongTermDebt2024	1499965	usd
CY2023Q4	iccc	Long Term Debt2025 LongTermDebt2025	3315970	usd
CY2023Q4	iccc	Long Term Debt2026 LongTermDebt2026	793438	usd
CY2023Q4	iccc	Long Term Debt2027 LongTermDebt2027	344110	usd
CY2023Q4	iccc	Long Term Debt Thereafter LongTermDebtThereafter	4587013	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	11969303	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	342880	usd
CY2023	iccc	Number Of Executive Officers NumberOfExecutiveOfficers	3	pure
CY2022Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	222379	usd
CY2023Q4	us-gaap	Other Deferred Compensation Arrangements Liability Current OtherDeferredCompensationArrangementsLiabilityCurrent	300000	usd
CY2023Q1	us-gaap	Other Deferred Compensation Arrangements Liability Current OtherDeferredCompensationArrangementsLiabilityCurrent	100000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	200000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	100000	usd
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	1	pure
CY2023Q4	iccc	Capital Expenditures Committed CapitalExpendituresCommitted	41000	usd
CY2023Q4	us-gaap	Other Commitment OtherCommitment	2345000	usd
CY2023Q4	iccc	Inventory Production InventoryProduction	7000	usd
CY2023Q4	iccc	Other Obligations OtherObligations	307000	usd
CY2019Q3	us-gaap	Area Of Land AreaOfLand	14300	sqft
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2022Q3	us-gaap	Area Of Land AreaOfLand	15400	sqft
CY2022Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P20Y
CY2023Q4	us-gaap	Payments For Rent PaymentsForRent	20000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	488743	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4739077	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4571149	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4721385	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2194670	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2249182	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	348929	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	149176	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	36774	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	36404	usd
CY2023	us-gaap	Lease Cost LeaseCost	385703	usd
CY2022	us-gaap	Lease Cost LeaseCost	185580	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	248595	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	148302	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P19Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P20Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0711	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0554	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	946003	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	349744	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	356732	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	363870	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5949488	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8308717	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3587332	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4721385	usd
CY2016Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1123810	shares
CY2016Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5900003	usd
CY2016Q1	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	5313224	usd
CY2017Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	200000	shares
CY2017Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1050000	usd
CY2017Q3	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	1034164	usd
CY2017Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	417807	shares
CY2017Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.3
CY2017Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3049991	usd
CY2017Q4	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	2734173	usd
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1636364	shares
CY2019Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.5
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000002	usd
CY2019Q1	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	8303436	usd
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	515156	shares
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.25
CY2021Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4250038	usd
CY2021Q2	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	4233026	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.73
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.13
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.19
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.16
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.69
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.82
CY2023Q4	iccc	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested	6.43
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.82
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4000	shares
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18760	usd
CY2022	iccc	Stock Options Covering Shares StockOptionsCoveringShares	5000	shares
CY2022	iccc	Stock Options Coveringcash StockOptionsCoveringcash	30670	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1040	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10525	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	210500	shares
CY2022	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	9.39
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	619845	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2023	us-gaap	Employee Stock Ownership Plan Esop Weighted Average Purchase Price Of Shares Purchased EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased	70
CY2023	iccc	Exercisable And Transferable Description ExercisableAndTransferableDescription	The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).
CY2023	us-gaap	Investment Company Purchase Premium Per Share InvestmentCompanyPurchasePremiumPerShare	70
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Change Due To Subsequent Interim Measurement Weighted Average Expected Long Term Rate Of Return On Plan Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets	0.50	pure
CY2023	iccc	Right To Acquire Per Share RightToAcquirePerShare	0.005
CY2023	us-gaap	Employee Stock Ownership Plan Esop Plan Description EmployeeStockOwnershipPlanESOPPlanDescription	Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders held in June 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting of Stockholders held in June 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the expiration date of such plan by one year.
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17471669	usd
CY2023	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18567962	usd
CY2022	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4627	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7672	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17471669	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18567962	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-8099	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	7334	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	96570	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	153100	usd
CY2023	us-gaap	Insurance Recoveries InsuranceRecoveries	365127	usd
CY2023	us-gaap	Other Income OtherIncome	107	usd
CY2022	us-gaap	Other Income OtherIncome	912	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21893	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-187190	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22619	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7658	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4627	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7672	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.01	pure
CY2018	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	563252	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4627	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7672	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1179474	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	576780	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	145802	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	88533	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	1325276	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	665313	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	1325276	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	665313	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4627	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7672	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1211694	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-522088	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-117149	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0203	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-47643	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0192	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	56214	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0097	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	36652	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0148	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	53241	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0092	pure
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	131361	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0528	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1325276	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0009	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	665313	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2676	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	5221	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.2297	pure
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	6799	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0027	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4627	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0008	pure
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7672	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0031	pure
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2121940	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2530472	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	726474	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	673233	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3729500	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3258395	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	886428	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	817617	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	592915	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	341683	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	50722	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	23370	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	37124	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	15587	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	32607	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	32787	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	100200	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	76554	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4034030	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2708754	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17471669	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13602385	usd
CY2023	us-gaap	Gross Profit GrossProfit	3869284	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4394852	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3088215	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2134295	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9617362	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5748078	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18567962	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10919183	usd
CY2022	us-gaap	Gross Profit GrossProfit	7648779	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4493872	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3190033	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2263817	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9947722	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2298943	usd
CY2023Q4	us-gaap	Assets Assets	43808102	usd
CY2022Q4	us-gaap	Assets Assets	44860649	usd
CY2023	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2739620	usd
CY2022	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2495241	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1892513	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3975274	usd
CY2023	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	231405	usd
CY2022	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	587677	usd
CY2023	us-gaap	Related Party Tax Expense Due From Affiliates Current RelatedPartyTaxExpenseDueFromAffiliatesCurrent	42507	usd
CY2022	us-gaap	Related Party Tax Expense Due From Affiliates Current RelatedPartyTaxExpenseDueFromAffiliatesCurrent	46426	usd
CY2023	iccc	Employees Salary Percentage EmployeesSalaryPercentage	1	pure
CY2023	iccc	Employees Salary Contribution Percentage EmployeesSalaryContributionPercentage	0.50	pure
CY2023	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	178150	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	159058	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2022	iccc	Payments Of Debt Discounts PaymentsOfDebtDiscounts		usd
CY2022	iccc	Change In Payments Of Debt Discounts Included In Accounts Payable And Accrued Expenses ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses		usd
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure		usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure		usd
CY2023Q4	iccc	Debt Discount Cost2026 DebtDiscountCost2026		usd
CY2023Q4	iccc	Debt Discount Cost2027 DebtDiscountCost2027		usd
CY2023Q4	iccc	Debt Discount Cost Thereafter DebtDiscountCostThereafter		usd
CY2022	us-gaap	Insurance Recoveries InsuranceRecoveries		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000811641

Files In Submission

Name	View Source	Status
0001213900-24-028718-index-headers.html	Edgar Link	pending
0001213900-24-028718-index.html	Edgar Link	pending
0001213900-24-028718.txt	Edgar Link	pending
0001213900-24-028718-xbrl.zip	Edgar Link	pending
ea0202277-10k_immu.htm	Edgar Link	pending
ea020227701ex10-11_immucell.htm	Edgar Link	pending
ea020227701ex10-8_immucell.htm	Edgar Link	pending
ea020227701ex23-1_immucell.htm	Edgar Link	pending
ea020227701ex31_immucell.htm	Edgar Link	pending
ea020227701ex32_immucell.htm	Edgar Link	pending
ea020227701ex97-1_immucell.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
iccc-20231231.xsd	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
iccc-20231231_cal.xml	Edgar Link	unprocessable
iccc-20231231_def.xml	Edgar Link	unprocessable
ea0202277-10k_immu_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
iccc-20231231_lab.xml	Edgar Link	unprocessable
iccc-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICCC
IMMUCELL CORP /DE/ Stock $iccc

2024 Q1 Form 10-K Financial Statement

#000121390024028718 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCC IMMUCELL CORP /DE/ Stock $iccc

2024 Q1 Form 10-K Financial Statement

#000121390024028718 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCC
IMMUCELL CORP /DE/ Stock $iccc